急性心力衰竭中的高钾血症:EAHFE登记研究的短期结局
EAHFE登记研究纳入45家西班牙急诊的13606例急诊急性心衰患者,中位年龄83岁,女性54%,中位血钾4.5 mEq/L(范围4.0-9.9)。以血钾4.0 mEq/L为参照,校正年龄、性别、合并症、基线状态和慢性治疗后,院内死亡风险从血钾≥4.8 mEq/L起持续升高(OR=1.35,95%CI 1.01-1.80),至血钾9.9 mEq/L时OR达8.41(95%CI 3.60-19.6)。非糖尿病患者高血钾时死亡风险更高,慢性使用盐皮质激素受体拮抗剂呈现混合效应;延长住院和出院后7天不良事件与血钾无关。作者据此提出,初始血钾>4.8 mEq/L的急诊急性心衰患者可能从积极的高钾血症治疗中获益。
要点
- 急诊急性心衰患者初始血钾>4.8 mEq/L与院内死亡独立相关,校正后OR从1.35(95%CI 1.01-1.80)升至血钾9.9 mEq/L时的8.41(95%CI 3.60-19.6)。
- 非糖尿病急性心衰患者血钾升高时院内死亡风险更高;慢性盐皮质激素受体拮抗剂治疗呈现混合效应。
- 血钾与延长住院(>7天)及出院后7天不良事件(急诊复诊、住院或死亡)均无关联。
- 作者认为初始血钾>4.8 mEq/L的急诊急性心衰人群可能从积极的高钾血症治疗中获益。
适用人群与场景
- 45家西班牙急诊科连续纳入的所有急诊急性心衰患者,共13606例;中位年龄83岁(IQR 76-88),女性占54%。
研究设计与关键结果
- 研究类型为EAHFE登记研究,纳入45家西班牙急诊的13606例急诊急性心衰患者,中位血钾4.5 mEq/L(IQR 4.3-4.9),范围4.0-9.9 mEq/L。
- 主要终点为全因院内死亡,发生率为7.7%;次要终点延长住院(>7天)发生率为35.9%,出院后7天不良事件(急诊复诊、住院或死亡)发生率为8.7%。
- 以血钾4.0 mEq/L为参照,用限制性立方样条曲线校正年龄、性别、合并症、患者基线状态和慢性治疗后,院内死亡风险从血钾≥4.8 mEq/L起持续升高(OR=1.35,95%CI 1.01-1.80),至血钾9.9 mEq/L时OR=8.41(95%CI 3.60-19.6)。
- 非糖尿病患者血钾升高时死亡风险更高;慢性使用盐皮质激素受体拮抗剂呈现混合效应。
- 延长住院和出院后7天不良事件均与血钾无关联。
- 针对主要终点进行了交互作用分析。
证据类型、等级与局限
- 证据类型:登记研究(EAHFE登记研究),原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急诊急性心衰患者初始血钾>4.8 mEq/L与院内死亡独立相关,该人群可能从积极的高钾血症治疗中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Both hyperkalemia (HK) and Acute Heart Failure (AHF) are associated with increased short-term mortality, and the management of either may exacerbate the other. As the relationship between HK and AHF is poorly described, our purpose was to determine the relationship between HK and short-term outcomes in Emergency Department (ED) AHF.
METHODS: The EAHFE Registry enrolls all ED AHF patients from 45 Spanish ED and records in-hospital and post-discharge outcomes. Our primary outcome was all-cause in-hospital death, with secondary outcomes of prolonged hospitalization (>7 days) and 7-day post-discharge adverse events (ED revisit, hospitalization, or death). Associations between serum potassium (sK) and outcomes were explored using logistic regression by restricted cubic spline (RCS) curves, with sK =4.0 mEq/L as the reference, adjusting by age, sex, comorbidities, patient baseline status and chronic treatments. Interaction analyses were performed for the primary outcome.
RESULTS: Of 13,606 ED AHF patients, the median (IQR) age was 83 (76-88) years, 54% were women, and the median (IQR) sK was 4.5 mEq/L (4.3-4.9) with a range of 4.0-9.9 mEq/L. In-hospital mortality was 7.7%, with prolonged hospitalization in 35.9%, and a 7-day post-discharge adverse event rate of 8.7%. Adjusted in-hospital mortality increased steadily from sK ≥4.8 (OR = 1.35, 95% CI = 1.01-1.80) to sK = 9.9 (8.41, 3.60-19.6). Non-diabetics with elevated sK had higher odds of death, while chronic treatment with mineralocorticoid-receptor antagonists exhibited a mixed effect. Neither prolonged hospitalization nor post-discharge adverse events was associated with sK.
CONCLUSION: In ED AHF, initial sK >4.8 mEq/L was independently associated with in-hospital mortality, suggesting that this cohort may benefit from aggressive HK treatment.
参考来源
- Rafique Z, Fortuny MJ, Kuo D, et al. Hyperkalemia in acute heart failure: Short term outcomes from the EAHFE registry. Am J Emerg Med. 2023. PMID: 37186977. doi:10.1016/j.ajem.2023.05.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。